lower schreef op 14 februari 2018 10:20:
[...]
Dhr. de Vries gaf tijdens de roadshow al aan dat Pharming de route via de verzekeraars kiest. Uniek ten opzichte van de concurrenten.
Met medisch specialisten die presenties geven, helemaal top.
Vragen? Leest het artikel in the Lancet.
Van de AVA vorig jaar:
You have made an interesting comparison in your presentation on the clinical trial results. Are there also any results of Shire and Haegarda, and would these be comparable to Ruconest?
Mr. De Vries:
Haegarda is also a C1-inhibitor with a high dose and the results are good and adequate. On the other hand, in terms of production as a result of the huge amounts of blood that need to be donated and the cumulative risks to which the patients are exposed when using such product in a chronic/ prophylactic therapy, we believe a recombinant product could be a good alternative once approved for use in such a setting. The switch to recombinant products is something that is currently going on in the market in general and Ruconest, being the sole recombinant product available, should hopefully benefit from that. Secondly, the future product of Shire, the antibody, works on another pathway as it is not a protein replacement therapy. The community is waiting for the results of this product, so it is hard to compare these results to Ruconest at this stage.
Deze ook interessant
[GeldIsOokNietAlles] GeldIsOokNietAlles 13 feb 2018 om 22:09
2
Iemand deze ooit gezien?
www.drugs.com/compare/cinryze-vs-fira...For Hereditary Angioedema Ruconest works perfect for me! I can self-administer and it works much quicker than Berinert and Firazyr. Also no issues with side effects so far.